On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global ...

Dr. Soon-Shiong joins Nobel laureates, former NIH directors, and leading oncology pioneers in Washington, D.C. to chart a path toward defeating cancer by 2035, with the discussion streamed live at ...

ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...

The clinical stage immunotherapy company logged a five-fold increase in fourth-quarter revenue of $38.3 million, and beat Wall Street's forecast of $37.9 million, according to FactSet. The top-line ...

ImmunityBio, Inc. (NASDAQ:IBRX), a commercial-stage immunotherapy company, disclosed significant financial and operational ...

As of Monday, February 23, ImmunityBio, Inc.’s IBRX share price has surged by 20.31%, which has investors questioning if this ...

On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal ...

Shares of Culver City-based immunotherapy company ImmunityBio Inc. had a huge runup in January, more than tripling in value ...

ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal ...